2025-05-16 - Analysis Report
Okay, here's an analysis of Recursion Pharmaceuticals Inc. (RXRX), based on the data you provided. The report is in English, with key numbers and brief analyses following each point.

**Report on Recursion Pharmaceuticals Inc. (RXRX)**

Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to discover and develop novel therapeutics.

**1. Performance vs. S&P 500 (VOO)**

*   **Accumulated Return (RXRX):** -60.43%
*   **Accumulated Return (VOO):** 21.84%
*   **Deviation (max: 28.3, min: -82.3, current: -82.3):** -82.3
*   **Relative Deviation:** 0.0

**Analysis:** RXRX has significantly underperformed the S&P 500 (VOO). The current deviation is at its lowest point relative to the historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha   | Beta | Cap(B) |
|------------|--------|--------|---------|------|--------|
| 2021-2023  | 5.0%   | 73.6%  | -10.0%  | -0.0 | 4.0    |
| 2022-2024  | 0.0%   | 73.6%  | -21.0%  | 0.0 | 2.8    |
| 2023-2025  | -9.0%  | 73.6%  | -30.0%  | -0.0 | 1.7    |

**Analysis:**
*   **CAGR:** The Compounded Annual Growth Rate has been declining and is currently negative, indicating a downward trend in returns over the analyzed periods.
*   **MDD:** The Maximum Drawdown remains consistently high at 73.6% across all periods, signifying significant risk and volatility in the investment.
*   **Alpha:** The consistently negative Alpha values indicate underperformance relative to the benchmark, with the underperformance worsening over time.
*   **Beta:** The Beta values close to zero suggest that the stock's returns are not strongly correlated with the market's overall movements.
*   **Cap(B):** The market capitalization has decreased from 4 billion to 1.7 billion, reflecting a substantial loss in investor value.

**2. Recent Price Action**

*   **Current Price:** 4.2451
*   **Last Market Data:** price: 4.2422, previousClose: 4.31, change: -1.57%
*   **5-Day Moving Average:** 4.359
*   **20-Day Moving Average:** 5.1808
*   **60-Day Moving Average:** 6.1017

**Analysis:** The current price is below all three moving averages (5, 20, and 60-day), indicating a downtrend. The recent market activity shows a decrease in price, reflecting negative sentiment.

**3. Market Risk Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.35 (Low Risk)
*   **RSI:** 30.28 (Approaching Oversold)
*   **PPO:** -1.7956
*   **Recent (20-day) Relative Deviation Change:** 0.0 (Negative)
*   **Last Market Data:** price: 4.2422, previousClose: 4.31, change: -1.57% (Reflecting the negative change)
*   **Expected Return (%):** -3665.3%

**Analysis:**
*   The MRI indicates a low-risk environment.
*   The RSI is nearing oversold territory, which *could* suggest a potential for a rebound, though not necessarily.
*   The negative PPO reinforces the downtrend.
*   The large negative expected return suggests significant risk and potential underperformance compared to the S&P 500 over the long term.
*   Given {'price': 4.2422, 'previousClose': 4.31, 'change': -1.57}, the relatively small percentage change doesn't represent an extreme event.

**4. Recent News & Significant Events**

*   **2025-05-13:** Recursion Pharmaceuticals Inc (RXRX) has recently made headlines due to major business developments, regulatory changes, or market events.
*   **2025-05-14:** Analysts are discussing Recursion Pharmaceuticals Inc's (RXRX) recent performance and its outlook in the context of industry trends and global economic factors.
*   **2025-05-16:** Recursion Pharmaceuticals Inc (RXRX)'s stock has shown notable volatility, influenced by recent news, earnings reports, or executive actions.
*   **2025-05-15:** Market experts highlight both risks and opportunities for Recursion Pharmaceuticals Inc (RXRX), advising investors to monitor recent news and company announcements.

**Analysis:** Recent news indicates volatility and potential significant events influencing the stock. Monitoring company announcements and industry trends is crucial.

**5. Recent Earnings Analysis**

| 날짜         | EPS    | 매출      |
|--------------|--------|-----------|
| 2025-05-05   | -0.5   | 0.01 B$   |
| 2024-11-06   | -0.34  | 0.03 B$   |
| 2024-08-08   | -0.4   | 0.01 B$   |
| 2024-05-09   | -0.39  | 0.01 B$   |
| 2025-05-05   | -0.39  | 0.01 B$   |

**Analysis:** The company consistently reports negative EPS (Earnings Per Share), and revenue remains relatively low (around $0.01-0.03 Billion), indicating ongoing losses. This is a significant concern.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue  | Profit Margin |
|--------------|----------|---------------|
| 2025-03-31   | $0.01B   | -47.31%       |
| 2024-12-31   | $0.00B   | -183.62%      |
| 2024-09-30   | $0.03B   | 53.69%        |
| 2024-06-30   | $0.01B   | 36.14%        |
| 2024-03-31   | $0.01B   | 17.23%        |

**Capital and Profitability:**

| Quarter      | Equity   | ROE        |
|--------------|----------|------------|
| 2025-03-31   | $0.93B   | -21.68%    |
| 2024-12-31   | $1.03B   | -17.29%    |
| 2024-09-30   | $0.52B   | -18.27%    |
| 2024-06-30   | $0.58B   | -16.69%    |
| 2024-03-31   | $0.40B   | -22.78%    |

**Analysis:**

*   **Revenue and Profitability:** Revenue fluctuates, and Profit Margins are highly variable. The negative profit margins in recent quarters are concerning.
*   **Capital and Profitability:** While Equity is substantial, negative ROE (Return on Equity) indicates that the company is not generating profits from shareholder investments.

**7. Overall Analysis**

Recursion Pharmaceuticals Inc. (RXRX) is currently facing significant challenges.

*   **Underperformance:** The stock has drastically underperformed the S&P 500.
*   **Downtrend:** Technical indicators (moving averages, PPO) confirm a downtrend.
*   **Financial Losses:** Consistent negative EPS, fluctuating revenue, and negative profit margins highlight financial difficulties.
*   **Volatility:** Recent news suggests the stock is subject to significant volatility.
*   **Long-Term Risks:** The extremely negative expected return indicates high risk for long-term investors.

**In conclusion, based on the provided data, RXRX appears to be a high-risk investment with significant challenges and negative momentum. Further research and due diligence are strongly advised before considering an investment.**
